1.The center for disease control-national nosocomial infection surveillance (CDC-NNIS) surgical patient risk index score and surgical site infections at UERMMMC.
Sunga Paul Anthony L ; Ampil Isaac David E ; Cortez Edgardo R ; Laudico Adriano V
Philippine Journal of Surgical Specialties 1994;49(2):55-59
The study retrospectively reviewed 1,029 general surgery operations performed from September 1, 1991 to May 31, 1993 to find out the association between the occurrence of surgical site infection (SSI) and the Centers for Disease Control-National Nosocomial Infection Surveillance (CDC-AWS) surgical patient risk index scores. The index assigned 1 point for each of 3 risk factors: 1) American Society of Anesthesiologists (ASA) preoperative assessment class 3, 4 or 5; 2) an operational classified as either contaminated or dirty-infected; 3) an operation with a duration longer than a specified increased with increasing contamination (p=0.000) as well as increasing index scores (p=0.000). Looking at operations within the same category of contamination, SSI rates also increased with increasing scores among clean operations (p=0.944), clean-contaminated operations (p=0.000), contaminated operations (p=0.559), and dirty operations. SSI rates in this hospital series were compared to the 44-hospital CDC-NNIS report.
Human ; Male ; Female ; Surgical Wound Infection ; Cross Infection ; Anesthesiologists
2.Primary hyperparathyroidism versus familial hypocalciuric hypercalcemia: a challenging diagnostic evaluation in an adolescent female
Mustafa TOSUR ; Monica E LOPEZ ; David L PAUL
Annals of Pediatric Endocrinology & Metabolism 2019;24(3):195-198
Primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcemia (FHH) have significantly different treatment approaches, so physicians must be careful to differentiate these 2 diseases. Herein, we report a 14-year-old female who presented with symptomatic hypercalcemia (12 mg/dL; reference range, 9.2–10.7 mg/dL), elevated intact parathyroid hormone (iPTH) (236 pg/mL; reference range, 9–69 pg/mL), and vitamin D deficiency (6 ng/mL; reference range, ≥ 20 ng/mL). On numerous occasions, her 24-hour urine calcium was more than 4 mg/kg/day, consistent with PHPT, but her fractional excretion of calcium on 24-hour urine collection was consistently below 1%, in line with FHH. ⁹⁹mTc-Sestamibi scan failed to detect any abnormalities. However, a 4-dimensional computed tomography scan of the neck revealed a right superior parathyroid adenoma which was excised with a focused parathyroidectomy. Although the patient’s calcium and iPTH levels normalized, her nonspecific symptoms persisted. This case illustrates both the challenges of differentiating PHPT from FHH and the limitations of a first-line imaging tool in identifying a parathyroid adenoma.
Adolescent
;
Calcium
;
Female
;
Humans
;
Hypercalcemia
;
Hyperparathyroidism, Primary
;
Neck
;
Parathyroid Hormone
;
Parathyroid Neoplasms
;
Parathyroidectomy
;
Reference Values
;
Urine Specimen Collection
;
Vitamin D Deficiency
3.Cryoablation and cementoplasty of a pathologic fracture in the sternum.
John A SWAN ; David M LIU ; Paul W CLARKSON ; Peter L MUNK
Singapore medical journal 2013;54(10):e215-7
A 49-year-old man with metastatic melanoma and pathologic fracture of the sternum was deemed to be a poor candidate for general anaesthesia. He suffered severe pain and range of motion limitation that did not respond to narcotic therapy. Ultimately, the lesion was managed with computed tomography-guided cryoablation and subsequent cementoplasty, and saw good initial clinical results.
Cementoplasty
;
methods
;
Cryosurgery
;
methods
;
Follow-Up Studies
;
Fractures, Spontaneous
;
diagnostic imaging
;
surgery
;
Humans
;
Male
;
Middle Aged
;
Sternum
;
diagnostic imaging
;
injuries
;
surgery
;
Tomography, X-Ray Computed
4.Firefighting and Cancer: A Meta-analysis of Cohort Studies in the Context of Cancer Hazard Identification
Nathan L. DEBONO ; Robert D. DANIELS ; Laura E. Beane FREEMAN ; Judith M. GRABER ; Johnni HANSEN ; Lauren R. TERAS ; Tim DRISCOLL ; Kristina KJAERHEIM ; Paul A. DEMERS ; Deborah C. GLASS ; David KRIEBEL ; Tracy L. KIRKHAM ; Roland WEDEKIND ; Adalberto M. FILHO ; Leslie STAYNER ; Mary K. SCHUBAUER-BERIGAN
Safety and Health at Work 2023;14(2):141-152
Objective:
We performed a meta-analysis of epidemiological results for the association between occupational exposure as a firefighter and cancer as part of the broader evidence synthesis work of the IARC Monographs program.
Methods:
A systematic literature search was conducted to identify cohort studies of firefighters followed for cancer incidence and mortality. Studies were evaluated for the influence of key biases on results. Random-effects meta-analysis models were used to estimate the association between ever-employment and duration of employment as a firefighter and risk of 12 selected cancers. The impact of bias was explored in sensitivity analyses.
Results:
Among the 16 included cancer incidence studies, the estimated meta-rate ratio, 95% confidence interval (CI), and heterogeneity statistic (I2) for ever-employment as a career firefighter compared mostly to general populations were 1.58 (1.14–2.20, 8%) for mesothelioma, 1.16 (1.08–1.26, 0%) for bladder cancer, 1.21 (1.12–1.32, 81%) for prostate cancer, 1.37 (1.03–1.82, 56%) for testicular cancer, 1.19 (1.07–1.32, 37%) for colon cancer, 1.36 (1.15–1.62, 83%) for melanoma, 1.12 (1.01–1.25, 0%) for non-Hodgkin lymphoma, 1.28 (1.02–1.61, 40%) for thyroid cancer, and 1.09 (0.92–1.29, 55%) for kidney cancer. Ever-employment as a firefighter was not positively associated with lung, nervous system, or stomach cancer. Results for mesothelioma and bladder cancer exhibited low heterogeneity and were largely robust across sensitivity analyses.
Conclusions
There is epidemiological evidence to support a causal relationship between occupational exposure as a firefighter and certain cancers. Challenges persist in the body of evidence related to the quality of exposure assessment, confounding, and medical surveillance bias.
5.BNT162B2 COVID-19 mRNA vaccination did not promote substantial anti-syncytin-1 antibody production nor mRNA transfer to breast milk in an exploratory pilot study.
Citra N Z MATTAR ; Winston KOH ; Yiqi SEOW ; Shawn HOON ; Aparna VENKATESH ; Pradip DASHRAATH ; Li Min LIM ; Judith ONG ; Rachel LEE ; Nuryanti JOHANA ; Julie S L YEO ; David CHONG ; Lay Kok TAN ; Jerry K Y CHAN ; Mahesh CHOOLANI ; Paul Anantharajah TAMBYAH
Annals of the Academy of Medicine, Singapore 2022;51(5):309-312
6.Nanomedicine and nanoparticle‑based delivery systems in plastic and reconstructive surgery
Jea Giezl N. SOLIDUM ; Jeremy A. CERIALES ; Erika P. ONG ; Eric David B. ORNOS ; Ruth Joy L. RELADOR ; Elgin Paul B. QUEBRAL ; Jose Florencio F. LAPEÑA JR. ; Ourlad Alzeus G. TANTENGCO ; Ka Yiu LEE
Maxillofacial Plastic and Reconstructive Surgery 2023;45(1):15-
Background:
Nanotechnology and nanomedicine are rising novel fields in plastic and reconstructive surgery (PRS).The use of nanomaterials often goes with regenerative medicine. Due to their nanoscale, these materials stimulate repair at the cellular and molecular levels. Nanomaterials may be placed as components of nanocomposite polymers allowing enhancement of overall biochemical and biomechanical properties with improved scaffold properties, cellular attachment, and tissue regeneration. They may also be formulated as nanoparticle-based delivery systems for controlled release of signal factors or antimicrobials, for example. However, more studies on nanoparticle-based delivery systems still need to be done in this field. Nanomaterials are also used as frameworks for nerves, tendons, and other soft tissues.Main body In this mini-review, we focus on nanoparticle-based delivery systems and nanoparticles targeting cells for response and regeneration in PRS. Specifically, we investigate their roles in various tissue regeneration, skin and wound healing, and infection control. Cell surface-targeted, controlled-release, and inorganic nanoparticle formulations with inherent biological properties have enabled enhanced wound healing, tumor visualization/imaging, tissue viability, and decreased infection, and graft/transplantation rejection through immunosuppression.
Conclusions
Nanomedicine is also now being applied with electronics, theranostics, and advanced bioengineering technologies. Overall, it is a promising field that can improve patient clinical outcomes in PRS.
7.Identification of new genetic risk factors for prostate cancer.
Michelle GUY ; Zsofia KOTE-JARAI ; Graham G GILES ; Ali Amin Al OLAMA ; Sarah K JUGURNAUTH ; Shani MULHOLLAND ; Daniel A LEONGAMORNLERT ; Stephen M EDWARDS ; Jonathan MORRISON ; Helen I FIELD ; Melissa C SOUTHEY ; Gianluca SEVERI ; Jenny L DONOVAN ; Freddie C HAMDY ; David P DEARNALEY ; Kenneth R MUIR ; Charmaine SMITH ; Melisa BAGNATO ; Audrey T ARDERN-JONES ; Amanda L HALL ; Lynne T O'BRIEN ; Beatrice N GEHR-SWAIN ; Rosemary A WILKINSON ; Angela COX ; Sarah LEWIS ; Paul M BROWN ; Sameer G JHAVAR ; Malgorzata TYMRAKIEWICZ ; Artitaya LOPHATANANON ; Sarah L BRYANT ; null ; null ; null ; Alan HORWICH ; Robert A HUDDART ; Vincent S KHOO ; Christopher C PARKER ; Christopher J WOODHOUSE ; Alan THOMPSON ; Tim CHRISTMAS ; Chris OGDEN ; Cyril FISHER ; Charles JAMESON ; Colin S COOPER ; Dallas R ENGLISH ; John L HOPPER ; David E NEAL ; Douglas F EASTON ; Rosalind A EELES
Asian Journal of Andrology 2009;11(1):49-55
There is evidence that a substantial part of genetic predisposition to prostate cancer (PCa) may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we consider that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed. Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare.
Genetic Predisposition to Disease
;
genetics
;
Genetic Testing
;
Humans
;
Kallikreins
;
genetics
;
Male
;
Membrane Proteins
;
genetics
;
Prostatic Neoplasms
;
diagnosis
;
genetics
;
Prostatic Secretory Proteins
;
genetics
;
Protein-Serine-Threonine Kinases
;
genetics
;
Risk Factors
8.Silent Intracerebral Hemorrhage in Patients Randomized to Stenting or Endarterectomy for Symptomatic Carotid Stenosis
Mandy D MÜLLER ; Lisa M JONGEN ; Aysun ALTINBAS ; Kristine A BLACKHAM ; Paul J NEDERKOORN ; Sumaira MACDONALD ; Rolf JÄGER ; Thomas WOLFF ; Philippe A LYRER ; L Jaap KAPPELLE ; Stephan G WETZEL ; Toby RICHARDS ; Jeroen HENDRIKSE ; Gert J DE BORST ; H Bart VAN DER WORP ; Stefan T ENGELTER ; David J WERRING ; Martin M BROWN ; Leo H BONATI
Journal of Stroke 2019;21(1):116-119
No abstract available.
Carotid Stenosis
;
Cerebral Hemorrhage
;
Endarterectomy
;
Humans
;
Stents
9.Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma.
Na QIN ; Yuancheng LI ; Cheng WANG ; Meng ZHU ; Juncheng DAI ; Tongtong HONG ; Demetrius ALBANES ; Stephen LAM ; Adonina TARDON ; Chu CHEN ; Gary GOODMAN ; Stig E BOJESEN ; Maria Teresa LANDI ; Mattias JOHANSSON ; Angela RISCH ; H-Erich WICHMANN ; Heike BICKEBOLLER ; Gadi RENNERT ; Susanne ARNOLD ; Paul BRENNAN ; John K FIELD ; Sanjay SHETE ; Loic LE MARCHAND ; Olle MELANDER ; Hans BRUNNSTROM ; Geoffrey LIU ; Rayjean J HUNG ; Angeline ANDREW ; Lambertus A KIEMENEY ; Shan ZIENOLDDINY ; Kjell GRANKVIST ; Mikael JOHANSSON ; Neil CAPORASO ; Penella WOLL ; Philip LAZARUS ; Matthew B SCHABATH ; Melinda C ALDRICH ; Victoria L STEVENS ; Guangfu JIN ; David C CHRISTIANI ; Zhibin HU ; Christopher I AMOS ; Hongxia MA ; Hongbing SHEN
Frontiers of Medicine 2021;15(2):275-291
Although genome-wide association studies have identified more than eighty genetic variants associated with non-small cell lung cancer (NSCLC) risk, biological mechanisms of these variants remain largely unknown. By integrating a large-scale genotype data of 15 581 lung adenocarcinoma (AD) cases, 8350 squamous cell carcinoma (SqCC) cases, and 27 355 controls, as well as multiple transcriptome and epigenomic databases, we conducted histology-specific meta-analyses and functional annotations of both reported and novel susceptibility variants. We identified 3064 credible risk variants for NSCLC, which were overrepresented in enhancer-like and promoter-like histone modification peaks as well as DNase I hypersensitive sites. Transcription factor enrichment analysis revealed that USF1 was AD-specific while CREB1 was SqCC-specific. Functional annotation and gene-based analysis implicated 894 target genes, including 274 specifics for AD and 123 for SqCC, which were overrepresented in somatic driver genes (ER = 1.95, P = 0.005). Pathway enrichment analysis and Gene-Set Enrichment Analysis revealed that AD genes were primarily involved in immune-related pathways, while SqCC genes were homologous recombination deficiency related. Our results illustrate the molecular basis of both well-studied and new susceptibility loci of NSCLC, providing not only novel insights into the genetic heterogeneity between AD and SqCC but also a set of plausible gene targets for post-GWAS functional experiments.
Adenocarcinoma of Lung/genetics*
;
Carcinoma, Non-Small-Cell Lung/genetics*
;
Carcinoma, Squamous Cell/genetics*
;
Genetic Heterogeneity
;
Genetic Predisposition to Disease
;
Genome-Wide Association Study
;
Humans
;
Lung Neoplasms/genetics*
;
Polymorphism, Single Nucleotide